Inimmune
Inimmune is a clinical-stage, privately held biotech developing disease-modifying immunotherapies and vaccine adjuvants based on proprietary synthetic TLR, Mincle, and STING agonists, with lead programs INI-2004 in Phase 2 for allergic rhinitis and INI-4001 in Phase 1 for solid tumors, targeting pharma partners via licensing and co-development.
- Company typePrivate
- Founded2016
- HeadquartersMissoula, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Inimmune does
Inimmune Corporation is a privately held, clinical-stage biotechnology company founded in 2016 in Missoula, Montana, by a team of former GSK Vaccines scientists. The company is developing a portfolio of disease-modifying immunotherapies and vaccine adjuvants built around proprietary synthetic agonists of innate immune receptors — primarily Toll-like receptors (TLR4, TLR7/8), Mincle, and STING — formulated in proprietary nanoparticle and adjuvant systems. Its lead clinical asset, INI-2004 (intranasal TLR4 agonist), has completed Phase 1 for allergic rhinitis and entered a pivotal Phase 2 allergen chamber trial in early 2026; the second clinical asset, INI-4001 (TLR7/8 agonist in a proprietary nanoparticle), is in Phase 1 for solid tumors, both as monotherapy and in combination with checkpoint inhibitors. The company is also advancing a deep pre-clinical and translational pipeline including the anti-opioid vaccine program (NIH HEAL), the Mincle-agonist INI-1098 for tuberculosis (NIH contract), the combination adjuvant TRAC478, and the T4Q/T4AH adjuvant systems partnered with SPI Pharma.
Inimmune is pre-revenue and operates a partnership-and-licensing business model: monetization is expected through co-development agreements, out-licensing of pipeline assets, milestone payments, and ultimately commercial supply of adjuvant systems to pharmaceutical partners, supplemented by substantial non-dilutive NIH funding (~$34M HEAL contract, $12.3M TB adjuvant contract, up to $9M NIAID contract). The company raised a $22 million Series A in July 2020 led by Two Bear Capital (the largest Series A in Montana history) and has since been actively seeking a Series A extension. The company maintains 11–50 employees at its Montana headquarters, has appointed a new CMO (Dr. Ferdinand Massari) and Head of Financial Strategy (Ryan McMillian) in March 2026 ahead of the INI-2004 Phase 2 readout, and is presently expanding into European consortia (EU4Health intranasal influenza vaccine) while broadening its allergy franchise from allergic rhinitis into food allergies and allergic asthma.
Inimmune firmographics
Firmographics- Name
- Inimmune
- Legal name
- Inimmune Corporation
- Website
- https://inimmune.com
- Company type
- Private
- Founded year
- 2016
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Inimmune is a clinical-stage, privately held biotech developing disease-modifying immunotherapies and vaccine adjuvants based on proprietary synthetic TLR, Mincle, and STING agonists, with lead programs INI-2004 in Phase 2 for allergic rhinitis and INI-4001 in Phase 1 for solid tumors, targeting pharma partners via licensing and co-development.
- Ownership category
- akta.pro rank
Inimmune industry classification
Industry- Product category
- Biopharmaceutical Immunotherapeutics
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Vaccine Adjuvants & Formulation Systems (HLAIAEAI)
- akta.pro secondary industries
- Immunology & Autoimmune Specialty Pharmaceuticals (HLAIACAB), Therapeutic Vaccines (e.g., Cancer/Chronic Infection) (HLAIAEAG), Clinical Development & Regulatory for Vaccines (trials, pharmacovigilance, lot release) (HLAAAEAK)
Keywords
Where Inimmune is headquartered
LocationHeadquarters
- HQ city
- Missoula
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Inimmune business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Infrastructure
Revenue model
- Licensing and Co-development Agreements: Pre-revenue clinical stage company with no commercial products. Revenue will be generated through licensing deals, co-development partnerships, and milestone payments with pharmaceutical partners. The company is actively seeking Series A extension investors.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels6 records
Inimmune product offering
Product offeringCore offering
Inimmune is a clinical-stage biotechnology company developing a portfolio of disease-modifying immunotherapies and vaccine adjuvants based on proprietary Toll-like receptor (TLR) agonist technology. The company focuses on innate immune system modulation, with clinical-stage assets including INI-2004 (TLR4 agonist for allergic rhinitis) and INI-4001 (TLR7/8 agonist for cancer immunotherapy), plus advanced adjuvant systems (T4Q, T4AH, TRAC478, INI-1098) and vaccine candidates targeting opioid use disorder and infectious diseases.
Product overview
Inimmune is a clinical-stage biotechnology company developing a portfolio of disease-modifying immunotherapies and vaccine adjuvants. The core products include INI-2004 (TLR4 agonist for allergic rhinitis, positioned as a pipeline-in-a-product with expansion potential into food allergies and allergic asthma) and INI-4001 (TLR7/8 agonist for cancer immunotherapy with dual use as vaccine adjuvant). The company also commercializes advanced adjuvant systems (T4Q, T4AH, TRAC478) through its SPI Pharma partnership and develops pre-clinical vaccine candidates for opioid addiction and infectious diseases. The portfolio is anchored on innate immune system modulation targeting TLRs, Mincle, and STING pathways.
Differentiator
Problem solved
Functional benefit
Products and services
- INI-2004 Allergen-agnostic immunotherapy targeting toll-like receptor 4 (TLR4) delivered as an intranasal spray for rapid disease-modifying treatment of allergic rhinitis; positioned as a pipeline-in-a-product with planned expansion into food allergies and allergic asthma. Currently in Phase 2 clinical trials.
- INI-4001 Synthetic TLR7/8 agonist formulated in a proprietary clinical nanoparticle for cancer immunotherapy; also used as a vaccine adjuvant for opioid and influenza vaccines. Engineered to stimulate innate immune pathways with potential as both monotherapy and in combination with checkpoint inhibitors for solid tumors.
- TRAC478 Combination adjuvant combining INI-2002 (TLR4 agonist) and INI-4001 (TLR7/8 agonist) designed to generate synergistic immune responses; produces strong Th1-biased antibody and T cell responses efficacious in influenza challenge models.
- INI-1098 Novel synthetic Mincle agonist developed as a Th17-generating adjuvant for bacterial and fungal pathogens including tuberculosis; manufactured under cGMP via an NIH-funded Adjuvant Development Contract.
- T4Q Adjuvant System Advanced adjuvant system combining INI-2002 (TLR4 agonist) with QS21 saponin; partnered with SPI Pharma for commercialization; offers improved stability and immunogenicity over current clinical TLR4 + saponin combinations.
- T4AH Adjuvant System
Quantifiable outcome
- Phase I trial: 53% improvement in nasal volume post ragweed challenge at 500µg dose vs placebo
- +2 more outcomes
Companies that use Inimmune
Customer profileSegments3 records
Ideal customer profiles3 records
Inimmune technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature6 records
Inimmune partnerships and signals
Strategic signalPartnerships
13 partnerships are on record, tiered core and minor.
- SPI Pharma, Inc.corePartnership to develop and commercialize innovative vaccine adjuvant systems (T4Q and T4AH). SPI Pharma specializes in drug development services with over 60 commercially launched drugs globally. Collaboration focused on delivering affordable and accessible adjuvant systems.
- Boston Children's HospitalcoreCollaboration on adjuvant discovery and development projects with Drs. Ofer Levy and David Dowling. Current projects focused on development of adjuvanted opioid and pertussis vaccines. Supported by NIH/NIAID Vaccine Adjuvant Development Program contract up to $9 million over 5 years.
- Cleveland CliniccoreLong-standing collaboration with Dr. Ted Ross at Cleveland Clinic working on developing an adjuvanted universal influenza vaccine.
- Columbia UniversitycoreCollaboration with Dr. Sandra Comer at Columbia University for opioid vaccine development efforts. Dr. Comer is a leader in opioid vaccine clinical trials.
- Duke UniversitycoreCollaboration with Drs. Herman Staats and Brandi Johnson-Weaver at Duke for development of sublingual food allergy treatment using INI-2004 as an adjuvant.
- Icahn School of Medicine at Mount SinaicoreCollaboration with Drs. Florian Krammer and Adolfo Garcia-Sastre on multiple projects focused on developing new adjuvanted influenza vaccines.
- Intrommune Therapeutics, Inc.coreCo-development of adjuvanted food allergy treatment combining INI-2004 with Intrommune's clinical-stage oral mucosal immunotherapy INT301 for peanut allergy. Collaboration to evaluate combining the two clinical-stage immunotherapies for rapid and long-term relief.
- Oregon Health Science University (OHSU)minorCollaboration with Dr. Victor DeFilippis on STING adjuvant discovery project at OHSU.
- University of ChicagominorCollaboration with Dr. Aaron Esser-Kahn on discovering novel combination adjuvants. Academic-industry partnership to develop next-generation vaccine adjuvants.
- University of MontanacoreCollaboration with Center for Translational Medicine Adjuvant Research Team on multiple projects including opioid vaccine, TRAC478 vaccine adjuvant, and INI-1098 vaccine adjuvant development projects.
- University of North CarolinacoreCollaboration with Drs. Mike Kulis and Johanna Smeekens at UNC on development of sublingual food allergy therapy.
- University of WashingtonminorCollaboration with Dr. Marco Pravetoni on opioid vaccine development project and Dr. Michael Gale on early-stage adjuvant discovery project.
- Medical University of ViennacoreEuropean consortium led by Medical University of Vienna to develop next-generation intranasal influenza vaccine. Consortium aims to be selected under EU4Health programme with budget of EUR 147,951,410. Inimmune contributes proprietary adjuvant INI-4001 and formulation expertise.
Scale indicators6 records
Recent moves6 records
Expansion highlights6 records
Inimmune competitors and assessment
Company assessmentDirect peers
- Dynavax Technologies: Dynavax is a commercial-stage biopharmaceutical company focused on vaccines and adjuvants, with the CpG 1018 TLR9 adjuvant platform used in approved COVID and hepatitis B vaccines. Most directly comparable to Inimmune's TLR-based adjuvant business and vaccine development focus.
- Adjuvance Technologies: Adjuvance Technologies is a privately-held biotechnology company developing saponin-based adjuvants including TQL1055, a next-generation semi-synthetic saponin. Directly competes with Inimmune's T4Q (TLR4 + QS21 saponin) and T4AH adjuvant systems in the vaccine adjuvant market.
- Selecta Biosciences: Selecta Biosciences (now Cartesian Therapeutics) developed immune tolerance therapies and novel adjuvants using nanoparticle technology. Comparable to Inimmune in focusing on innate immune modulation and tolerogenic immunotherapies, though focused on autoimmune applications.
- Intrommune Therapeutics: Intrommune Therapeutics is a clinical-stage biotech developing INT301 oral mucosal immunotherapy for peanut and other food allergies. Direct partner with Inimmune combining INI-2004 with INT301 for next-generation allergy treatment.
Emerging players
- Checkmate Pharmaceuticals: Checkmate Pharmaceuticals developed CMP-001, a TLR9 agonist intratumoral therapy for melanoma before being acquired by Regeneron in 2022. Directly relevant precedent for TLR agonist development in oncology immunotherapy, similar to Inimmune's INI-4001 program.
- Bolt Biotherapeutics: Bolt Biotherapeutics developed immune-stimulating antibody conjugates (ISACs) targeting innate immunity for cancer treatment. Comparable clinical-stage oncology immunotherapy company using novel immune activation approaches, though with different mechanism than Inimmune's TLR agonists.
- CureVac: CureVac is a clinical-stage biopharmaceutical company developing mRNA-based vaccines and immunotherapies with proprietary adjuvant approaches. Comparable clinical-stage biotech developing novel vaccine technology, though using different mRNA platform.
Broad incumbents
- GSK (GlaxoSmithKline): GSK is a global pharmaceutical leader with the established AS01, AS04, and other proprietary adjuvant systems used in Shingrix, Cervarix, and other vaccines. Inimmune's founders came from GSK Vaccines and compete directly in the adjuvant space with this industry incumbent.
- Novavax: Novavax develops recombinant protein vaccines using its proprietary Matrix-M saponin-based adjuvant, comparable to Inimmune's T4Q and T4AH adjuvant systems. Broad incumbent in the vaccine adjuvant and development space.
- Stallergenes Greer: Stallergenes Greer is a global leader in allergen immunotherapy (AIT) for respiratory allergies, offering subcutaneous and sublingual treatments. Competes in the allergy immunotherapy market where Inimmune's INI-2004 is positioned as a disease-modifying alternative.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
Inimmune social profiles
Digital presenceInimmune financial estimates
Financial estimateRevenue estimate
Valuation estimate
Inimmune leadership team
Management profileNumber of profiles
Profiles16 records
Inimmune funding detail
Funding detailFunding overview
Funding rounds2 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Inimmune M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Inimmune
What does Inimmune do?
Inimmune is a clinical-stage biotechnology company developing a portfolio of disease-modifying immunotherapies and vaccine adjuvants based on proprietary Toll-like receptor (TLR) agonist technology. The company focuses on innate immune system modulation, with clinical-stage assets including INI-2004 (TLR4 agonist for allergic rhinitis) and INI-4001 (TLR7/8 agonist for cancer immunotherapy), plus advanced adjuvant systems (T4Q, T4AH, TRAC478, INI-1098) and vaccine candidates targeting opioid use disorder and infectious diseases.
Is Inimmune a public or private company?
Inimmune is a private company. It is classified as venture growth investor backed and is currently operating.
When was Inimmune founded?
Inimmune was founded in 2016. It employs 11 to 50 people.
Where is Inimmune based?
Inimmune is headquartered in Missoula, United States, in the North America region.
How does Inimmune make money?
One revenue line is on record: licensing and Co-development Agreements.
Who are Inimmune's main competitors?
Direct peers on record are Dynavax Technologies, Adjuvance Technologies, Selecta Biosciences and Intrommune Therapeutics. Emerging players are Checkmate Pharmaceuticals, Bolt Biotherapeutics and CureVac. Broad incumbents are GSK (GlaxoSmithKline), Novavax and Stallergenes Greer.
Does Inimmune have an API?
No public API is recorded for Inimmune.
What industry is Inimmune in?
Inimmune's product category is Biopharmaceutical Immunotherapeutics. Its primary akta.pro industry code is HLAIAEAI, Vaccine Adjuvants & Formulation Systems, with a secondary code of HLAIACAB, Immunology & Autoimmune Specialty Pharmaceuticals. Its NAICS code is 325414 and its SIC code is 2834.